Full Press Release Details
Solid Biosciences Doses First Participant in First in Class Phase 1b FALCON Trial Evaluating SGT-212 Dual Route Gene Therapy for the Treatment of Friedreich s Ataxia.
SLDB
Solid Biosciences Doses First Participant in First in Class Phase 1b FALCON Trial Evaluating SGT-212 Dual Route Gene Therapy for the Treatment of Friedreich s Ataxia
Key Takeaway: Solid Biosciences Doses First Participant in First in Class Phase 1b FALCON Trial Evaluating SGT-212 Dual Route Gene Therapy for the Treatment of Friedreich s Ataxia